Fundraising Fox

VarmX

Founded 2016 · 8 known investors

varmx.com ↗

VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). The therapy aims to stop severe bleeding and reduce bleeding risk during surgery for these patients.

BiotechMedical Devices

Investors · 8

Sound BioventuresMalmö
Ysios CapitalBarcelona · $5.4M – $21.6M
BGVreportedSilicon Valley
BioGeneration Venturesreported · 2 sourcesNaarden
EICreportedOrinda
EQT Life SciencesreportedLuxembourg · $11M – $66M
Inkefreported · 2 sourcesAmsterdam
Lundbeckfonden VenturesreportedCopenhagen

In the news

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery - BioSpacebiospace.com · Aug 2026VarmX raises €30M for blood clotting triallabiotech.eu · May 2023VarmX raises €30 million Series B2 financing – Ysios Capitalysioscapital.com · May 2023VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trialbusinesswire.com · May 2023VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulantshmpgloballearningnetwork.com · Jul 2020VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants - BioSpacebiospace.com · Jul 2018

Frequently asked questions

What does VarmX do?
VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). The therapy aims to stop severe bleeding and reduce bleeding risk during surgery for these patients.
Who are VarmX's investors?
VarmX's investors include Sound Bioventures, Ysios Capital, BGV, BioGeneration Ventures, EIC, EQT Life Sciences, Inkef, Lundbeckfonden Ventures.